Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1362560 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL8200633 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL1362558 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL29429783 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL2843089 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL25274089 | 0.88 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL1361732 | 0.88 | SLC10A2 (0.79) | SLC10A2 | |
| SCHEMBL919677 | 0.86 | SLC10A2 (0.62) | SLC10A2 | |
| SCHEMBL1361642 | 0.85 | SLC10A2 (0.74) | SLC10A2 | |
| SCHEMBL2946578 | 0.85 | SLC10A2 (0.74) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427713-B1 | BENZOTHIAZEPINE DERIVATIVES FOR THE TREATMENT OF HYPERLIPIDEMIA | ALBIREO AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-7125864-B2 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | ALBIREO AB (SE) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032776-A1 | Benzothiazepine derivatives for the treatment of hyperlipidemia | SLC10A2, SLC10A1, LCAT | SLC10A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.